These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1631 related articles for article (PubMed ID: 20228401)

  • 21. Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus.
    Ó Hartaigh B; Szymonifka J; Okin PM
    J Hypertens; 2018 Jan; 36(1):101-109. PubMed ID: 28832365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial.
    Soliman EZ; Byington RP; Bigger JT; Evans G; Okin PM; Goff DC; Chen H
    Hypertension; 2015 Dec; 66(6):1123-9. PubMed ID: 26459421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial.
    Barzilay JI; Howard AG; Evans GW; Fleg JL; Cohen RM; Booth GL; Kimel AR; Pedley CF; Cushman WC
    Diabetes Care; 2012 Jul; 35(7):1401-5. PubMed ID: 22723577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
    Xie X; Atkins E; Lv J; Bennett A; Neal B; Ninomiya T; Woodward M; MacMahon S; Turnbull F; Hillis GS; Chalmers J; Mant J; Salam A; Rahimi K; Perkovic V; Rodgers A
    Lancet; 2016 Jan; 387(10017):435-43. PubMed ID: 26559744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial.
    Dieter BP; Daratha KB; McPherson SM; Short R; Alicic RZ; Tuttle KR
    Am J Nephrol; 2019; 49(5):359-367. PubMed ID: 30939480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus.
    Berkowitz SA; Sussman JB; Jonas DE; Basu S
    J Am Coll Cardiol; 2018 Sep; 72(11):1214-1223. PubMed ID: 30189998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial.
    Foy CG; Lovato LC; Vitolins MZ; Bates JT; Campbell R; Cushman WC; Glasser SP; Gillespie A; Kostis WJ; Krousel-Wood M; Muhlestein JB; Oparil S; Osei K; Pisoni R; Segal MS; Wiggers A; Johnson KC;
    J Hypertens; 2018 Apr; 36(4):904-915. PubMed ID: 29493562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
    Nazarzadeh M; Bidel Z; Canoy D; Copland E; Bennett DA; Dehghan A; Davey Smith G; Holman RR; Woodward M; Gupta A; Adler AI; Wamil M; Sattar N; Cushman WC; McManus RJ; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):645-654. PubMed ID: 35878651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Blood Pressure Lowering Treatment Trialists' Collaboration
    Lancet; 2021 Sep; 398(10305):1053-1064. PubMed ID: 34461040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes.
    Mehler PS; Coll JR; Estacio R; Esler A; Schrier RW; Hiatt WR
    Circulation; 2003 Feb; 107(5):753-6. PubMed ID: 12578880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease.
    Cooper-DeHoff RM; Gong Y; Handberg EM; Bavry AA; Denardo SJ; Bakris GL; Pepine CJ
    JAMA; 2010 Jul; 304(1):61-8. PubMed ID: 20606150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
    Curb JD; Pressel SL; Cutler JA; Savage PJ; Applegate WB; Black H; Camel G; Davis BR; Frost PH; Gonzalez N; Guthrie G; Oberman A; Rutan GH; Stamler J
    JAMA; 1996 Dec; 276(23):1886-92. PubMed ID: 8968014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure-Lowering Therapy.
    Foy AJ; Filippone EJ; Schaefer E; Nudy M; Ruzieh M; Dyer AM; Chinchilli VM; Naccarelli GV
    JAMA Netw Open; 2021 Oct; 4(10):e2128980. PubMed ID: 34668944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
    Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
    JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
    Gaede P; Vedel P; Larsen N; Jensen GV; Parving HH; Pedersen O
    N Engl J Med; 2003 Jan; 348(5):383-93. PubMed ID: 12556541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.
    Oikonomou EK; Spatz ES; Suchard MA; Khera R
    Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
    Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 82.